SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-278560
Filing Date
2022-11-07
Accepted
2022-11-07 08:15:03
Documents
14
Period of Report
2022-11-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d409438d8k.htm   iXBRL 8-K 37257
2 EX-99.1 d409438dex991.htm EX-99.1 28835
6 GRAPHIC g409438g1106213710775.jpg GRAPHIC 3778
  Complete submission text file 0001193125-22-278560.txt   207425

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oyst-20221107.xsd EX-101.SCH 2529
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oyst-20221107_lab.xml EX-101.LAB 18068
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oyst-20221107_pre.xml EX-101.PRE 11334
8 EXTRACTED XBRL INSTANCE DOCUMENT d409438d8k_htm.xml XML 3590
Mailing Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 221363821
SIC: 2836 Biological Products, (No Diagnostic Substances)